Modulation of the immune response to SARS-CoV-2 vaccination by NSAIDs
Evidence is scarce to guide the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to mitigate SARS-CoV-2 vaccine related adverse effects, given the possibility of blunting the desired immune response. In this pilot study, we deeply phenotyped a small number of volunteers who did or did not take NSAIDs concomitant with SARS-CoV-2 immunizations to seek initial information on the immune response. A SARS-CoV-2 vaccine specific RBD-IgG antibody response and efficacy in the evoked neutralization titers were evident irrespective of concomitant NSAID consumption. Given the sample size, only a large and consistent signal of immunomodulation would have been detectable, and this was not apparent. However, the information gathered may inform the design of a definitive clinical trial.
COVID-19 Review Consortium:
The COVID-19 review consortium was initiated by Casey Greene's team in response to the coronavirus disease 2019 (COVID-19) pandemic. Led by Dr Halie Rando, the consortium has created a living review of which sections have been peer reviewed and published. Some of the main outputs of the review consortium are presented below.
SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics
https://greenelab.github.io/covid19-review/
SARS-CoV-2 and COVID-19: An Evolving Review of Diagnostics and Therapeutics
https://greenelab.github.io/covid19-review/